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BACKGROUND:  The time periods of pregnancy and lactation are recognized as 
times of changes in maternal weight and high bone turnover and theoretically can be 
transitional time periods regarding female body composition.  We aim to inquiry 
associations between postpartum body composition, breastfeeding, maternal 
docosahexaenoic acid (DHA) status and intake, and physical activity.  METHODS:  27 
women 37.3 ± 17.3 months postpartum participated.  Blood samples were assessed for D(A.  DEXA analyses provided body composition data.  Pearson’s correlations and linear 
regression models tested for significance.  RESULTS:  Total MET hours per week 
significantly positively correlated with whole body BMD and lumbar BMC.  Both physical 
activity and RBC DHA explained significant amounts of variance within lumbar and pelvic 
BMC.  CONCLUSIONS:  Associations between exercise and bone mineralization within the 
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A. HEALTH ISSUES AMONGST WOMEN OF CHILDBEARING AGE 
 The population of the United States (US) faces a number of health concerns.  
Amongst these are issues facing women of childbearing age.  Using data collected from the 
2011-2012 National Health and Nutrition Examination Survey (NHANES), it is estimated 
that approximately one-third of all US adult women (36.1%, adjusted for age) are obese 
with 31.8% of women aged 20-39 being classified as obese [1].   Additionally, 58.5% of US 
women within this age group classify as either obese or overweight [1]. Overweight and 
obesity are defined as a body mass index (BMI) of 25.0 – 29.9 kg/m2 or ≥  kg/m2 
(kilograms/meters2), respectively, by the National Heart, Blood, and Lung Institute 
(NHBLI) and are associated with increased adiposity [2].  Dating from 1960 to present day, 
obesity among women in the United States has increased by 20.8 percentage points (Figure 
1) [3].  Obesity has been recently estimated to increase the risk of all-cause mortality by 
18% (95% CI, 12-25%) compared to maintenance of a healthy weight (BMI between 18.5 
and 24.9 kg/m2) [2].  It is well established that overweight and obesity are related to 
hypertension, type 2 diabetes mellitus (T2DM), coronary heart disease (CHD), stroke, 
gallbladder disease, osteoarthritis, sleep apnea, respiratory problems, and some cancers 
such as endometrial and breast cancer [4].  Additionally, obesity has been associated with 
psychological disorders (specifically depression) and, amongst women specifically, 





Figure 1:  Changes in overweight and obesity prevalence since 1960. 
Fryar et al., 2014 
 
 Chu et al., when pooling data collected from 26 US states and New York City, 
estimated that in the United States, one in five women who delivered live births were obese 
during pregnancy [5].  Within two subgroups, African-American women and women whose 
delivery was paid for by Medicaid, one in three pregnant women were obese [5].  Unique 
risk factors are associated with increased adiposity in the time periods surrounding 
pregnancy as both conditions increase morbidity for mother and child [6]. During 
pregnancy, elevated BMI increases the risk for gestational diabetes, preeclampsia, maternal 
thrombosis (during both the antenatal and postnatal periods), postnatal hemorrhage, 
macrosomia, fetal shoulder dystocia, fetal death, as well as childhood obesity [5,6].  
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Additionally, as BMI increases, a corresponding increase in the numbers of cesarean 
deliveries has been observed in many studies; such deliveries can harbor additional 
complications, including an increase in maternal blood loss during delivery, an increased 
incidence of postoperative wound infections, and endometritis [6].  
Pregnancy itself can be a transitional period into overweight or obesity, placing 
women at risk for subsequent poor health outcomes and future pregnancy complications.  
It is important to consider that recent literature has shown between 15 and 20% of women 
will retain ≥ 5kg (10.4 lbs) of their gestational weight gain at 12 months postpartum [7].  In 
addition to failure to lose gestational weight in a reasonable timeframe, the risk of 
excessive weight retention (or transition to overweight or obesity) after pregnancy is also 
associated with the degree of obesity present prior to pregnancy as well as gestational 
weight gain above the recommended levels [7].  Evidence shows that women who fail to 
lose weight postpartum have a greater risk of long-term obesity [8].  Within the intra- and 
peripartum periods, maternal overweight and obesity increases the risk of development of 
T2DM, dyslipidemia, and cardiovascular disease (CVD) later in life [8].  A recent 
prospective study found that women who gained excessive amounts of weight during 
pregnancy, when compared to women who gained recommended amounts of weight 
during pregnancy as defined by the Institute of Medicine 2009 Guidelines (Figure 2), were 
47% (95% CI, 11-94%) more likely to develop diabetes when controlling for maternal age, 
parity, smoking, race, ethnicity, TV watching, and exercise [9, 10].  Much research has been 
conducted assessing the risk for transition to overweight and obesity postpartum.  In 
addition to the proposed risk for increased fat mass postpartum, it has also been postulated 
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that pregnancy as well as lactation could be transitional periods regarding a woman’s bone 
mineralization and thus possible risk for osteopenia and osteoporosis later in life [11]. 
 
Figure 2:  Institute of Medicine (IOM) 2009 guidelines for pregnancy weight gain. 
American College of Obstetricians and Gynecologists, 2013 
 
B.  PREGNANCY, LACTATION, AND BONE TURNOVER 
 In pregnancy and lactation both, the maternal environment adapts to meet the 
calcium demands of the developing fetus.  How this specifically affects maternal bone 
mineralization is not entirely understood.   It is known that during pregnancy, 2-3% of 
maternal calcium is transferred to the fetus with most of this occurring during the second 
and third trimesters [11].  In the final trimester, as calcium transfer increases to between 
110-120 mg/d, there is a possibility of net maternal decalcification despite upregulation of 
renal calcium retention and intestinal calcium absorption [12].   Mechanisms underlying 
these phenomena are still being elucidated.  Vitamin D has shown to possibly play a role in 
upregulating maternal calcium absorption, while parathyroid hormone (PTH) related 






Table 1. Institute of Medicine Weight Gain Recommendations for Pregnancy ^
   Recommended Rates 
    of Weight Gain† in the  
  Recommended Second and Third  
Prepregnancy Weight  Range of Trimesters (lb)  




of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) have been implicated 
in increasing bone resorption, allowing maternal calcium stores to supply calcium to the 
fetus as shown in Figure 3. 
 
                      
Figure 3:  Mechanisms underlying maternal bone turnover during pregnancy. 
E: estrogen, IGF-1: insulin-like growth factor 1, PGH: placental growth hormone, OPG: 
osteoprotegerin, PRL: prolactin, PTH: parathyroid hormone, PTHrp: parathyroid hormone 
related peptide, RANKL: receptor activator of nuclear factor kappa B ligand 
Sanz-Salvador et al., 2015 
 
It is also documented that during lactation, 300-400mg of calcium daily are 
transferred from the mother to the infant, with most of this coming from maternal bone 
stores [11].   During a period of 6 months of breastfeeding, women are estimated to lose 
between 5-10% of their total bone mass.  Mechanisms behind this have been poorly 
understood, however PTHrP is likely involved in stimulating bone turnover [11,12].  Much 
of the proposed bone loss has been documented to occur at sites of cortical bone such as 
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the lumbar spine and femoral neck [11].   Prolactin has shown to be an additional 
stimulator of bone resorption [11]. 
Because of the possibility of net loss of bone mineralization during these time 
periods, it has been hypothesized that pregnancy and lactation, specifically when 
considering factors such as multifetal pregnancies, parity, closely spaced pregnancies, 
discrepancies in environmental factors such as maternal diet and calcium intake, as well as 
duration and lifetime history of breastfeeding, could be considered risk factors for 
subsequent development of post-menopausal osteoporosis if appropriate measures are not 
taken to reduce bone loss [11].  However, most longitudinal studies suggest that within one 
year of weaning a child, maternal bone calcification returns to baseline [12].  Still, 
aforementioned confounding factors in addition to the role of pre- and postpartum physical 
activity levels complicate much of the present research.  Physical activity across the 
lifespan has associated with greater bone mineralization.  However, the effect of physical 
activity during periods of pregnancy and lactation on future risk for poor mineralization is 
unclear.  Dietary factors in pregnancy and lactation and their relationship with future bone 
mineralization is also presently poorly elucidated.  Postulated has been a role for proteins 
that are pro-inflammatory in promoting poor bone mass [13].  In osteoporosis, we know 
there is an inflammatory state akin to that seen with obesity.  It is also known that 
pregnancy is a pro-inflammatory period, thus the possibility that dietary interventions 
could help to reduce risk has proven to be of interest. 
C.  STRATEGIES FOR REDUCING RISK 
Presently in the United States, greater than 40% of pregnant women gain more 
weight than recommended during their pregnancy and an estimated 18% begin pregnancy 
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obese [14,15].  Strategies for the prevention of obesity and associated complications can 
therefore be conducted either during pregnancy or during the interpartum period.  A 
recent meta-analysis evaluated the effectiveness of maternal dietary and physical activity 
interventions during pregnancy at reducing gestational weight gain.  After reviewing 30 
randomized studies reporting intervention to promote recommended weight gain, women 
participating in an intervention were found to have gained 0.97 kg less than non-
intervention counterparts [16].  Women who participated specifically in a trial using a 
dietary intervention gained on average 3.36kg less than non-intervention counterparts 
[16].  Typical dietary interventions were often as simple as promotion of a balanced diet 
consisting of carbohydrates, fats, and protein while maintaining a food diary.  Standard 
physical activity interventions included promotion of light-intensity resistance training, 
walking for 30 minutes, or weight bearing exercises [16].  Dietary interventions were also 
found to reduce incidence of preeclampsia (RR 0.67, 95% CI 0.53 to 0.85; p = 0.0009), 
gestational hypertension (RR 0.30, 95% CI 0.10 to 0.88; p = 0.03), and preterm births (RR 
0.68, 95% CI 0.48 to 0.96; p = 0.03) [16].  Often, such interventions incorporate behavioral 
change theories such as the transtheoretical model to assess self-efficacy of individuals and 
readiness to adapt [17].  Low-intensity interventions, including measures such as 
counseling women on recommended gestational weight gain at the first prenatal visit, 
increasing weight monitoring, and discussing basic nutrition messages at each prenatal 
visit such as limiting consumption of sugary beverages have been proposed as basic, but 
needed additions to the present standard care [18]. 
Decreasing the degree of weight retention, particularly in between pregnancies, is 
important as there is an association with increased weight between pregnancies and long-
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term obesity [7].  Postpartum, breastfeeding has shown in some studies to assist in weight 
loss for women just having given birth.  This effect is often attributed to the increased 
caloric expenditure required for lactation or metabolic changes that are favorable to weight 
loss [19].  At present, some 40.7% of US women breastfeed their children through the first 
3 months of life and 18.8% breastfeed through the first 6 months of their child’s life [20].  
In a recent study, exclusive breastfeeding for 3 months led to a weight loss of 3.2 lbs 
greater than that seen in a matched cohort of women not breastfeeding exclusively for any 
duration of time [14].  Additionally, breastfeeding appeared to increase the chances of re-
attaining pre-pregnancy weight by 6.1% (95% CI: 1.0, 11.1) [14].  Given this, there is a clear 
documented relationship between breastfeeding and post-partum body weight changes; 
however, there has been little inquiry into the relationship between breastfeeding, 
postpartum weight loss, physical activity, and nutrient intakes.   
Dietary interventions can be an important strategy for health promotion.  Stendell-
Hollis and colleagues provided groups of breastfeeding women one of two diets 
postpartum, a Mediterranean diet or a diet based on the USDA My Pyramid for Pregnancy 
and Breastfeeding guidelines, and found that both groups of women had decreased TNF-  
levels at 4 months postpartum compared to baseline measures taken around the time of 
delivery, however there were no between group differences [7].  Dietary interventions such 
as supplementation of specific nutrients like docosahexaenoic acid (DHA) have also been 
conducted in pregnancy, but the majority of studies have focused on neonatal health and 




D.  DOCOSAHEXAENOIC ACID (DHA), PREGNANCY, AND THE BASIS FOR INTEREST 
 The very long-chain omega-3 (n-3) fatty acids eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) have been shown to play many physiological roles, including 
crucial roles in the maintenance of pregnancy and fetal cognitive development as well as 
inflammation, bone turnover, and possibly accumulation and storage of body fat [21].  
Given its molecular composition, DHA is important to the membrane composition of many 
highly specialized cells such as those of the central nervous system [22].  During pregnancy 
and lactation, DHA is of importance as it is transferred to child across the placenta and 
through breast milk [22].  Fetal DHA plasma phospholipids are roughly 300-fold greater 
than those found in maternal blood [22].  High concentrations of DHA in retinal tissue and 
brain grey matter suggest it is crucial to proper retinal and neural development [22].  
Additionally, low consumption of fish, a primary source of DHA, is associated with risk for 
preterm delivery; however, supplementation of DHA at levels of 600 mg/d decreases risk 
for early preterm birth (<34 weeks gestation) and very low birth weight, a risk factor for 
infant mortality and has been associated with T2DM later in life [23,24].  Cortical 
neuroplasticity, or the ability for neuronal cells to change over time, has associated with 
preterm birth, again indicating a possible link between DHA availability to the fetus or 
neonate and neural development [25].  Preterm supplementation of long chain 
polyunsaturated fatty acids (LCPUFAs) like DHA have shown beneficial effects on child 
neural development primarily when the n-6:n-3 is kept near 1:1 or 2:1 [26]. 
Inquiries into the effects of long chain n-3 fatty acids on health date back to the 
1980s.  These fatty acids proved to be of interest given their molecular composition, as the 
high degree of unsaturation meant that incorporation into cell membranes could lead to 
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changes in the fluidity of the cell membranes [27].  More recently, DHA through 
mechanisms not completely elucidated may play a role in they biosynthesis of extracellular 
signaling molecules such as prostaglandins (PGs) [21].  DHA has shown to reduce synthesis 
of metabolites derived from arachidonic acid (AA) as DHA intake, via incorporation into 
cell membranes, inhibits cyclooxygenase activity by displacing AA from the phospholipid 
bilayer [21].  
DHA may affect bone turnover via fatty acid derivatives such as prostaglandins and 
may involve affects on the receptor activator of NF-κB (RANK) found on osteoclasts, 
responsible for bone resorption.  DHA, likely through its displacement of AA from cell 
membranes and later conversion to anti-inflammatory mediators, reduces the availability 
of AA for prostaglandin-2 (PGE2) synthesis [28].  PGE2 stimulates both RANK and RANK 
ligand (RANKL) upregulation, and thus bone resorption.  DHA, through displacement, may 
diminish RANKL production and has been implicated in limiting osteoclast maturation 
while upregulating osteoblast maturation [29].  Supporting this, animal studies have found 
DHA supplementation to correlate with greater osteoblast density, less osteoclast activity, 
and greater bone mass [29].  
A graphic for proposed mechanisms of action for DHA within the context of bone 
health is described in Figure 4.  In the small intestine, DHA has shown in animal studies to 
possibly upregulate calcium absorption acting on calcium ATP transferase proteins (Ca2+ 
ATPase) [28].  Within bone, DHA may act in two different ways to promote bone 
mineralization.  One is to inhibit pre-osteoclast (pre-OC) cell advancement to mature 
osteoclasts (mature OC).  This likely occurs in part through reduction of AA within 
osteoblast (OB) cell membranes [28].  Additionally, DHA through poorly understood 
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mechanisms might also promote differentiation of mesenchymal stem cells (MSC) to 
osteoblasts, thus maintaining levels of active bone forming cells [28]. 
 
                         
 
Figure 4:  Possible mechanisms of action for DHA in bone health 
AA: arachidonic acid, Ca2+ ATPase: calcium ATP transferase, DHA: docosahexaenoic acid, 
LA: linoleic acid, MSC: mesenchymal stem cell, OB: osteoblast, OC: osteoclast, OPG: 
osteoprotegerin, RANK: receptor activator of nuclear factor kappa B, RANKL: receptor 
activator of nuclear factor kappa B ligand 
Lau et al., 2013 
 
DHA has additionally been described as a precursor for D-series resolvins and 
protectins, lipid mediators that act to resolve the inflammatory process [30].  Resolvins D1 
and D2 have shown to increase adiponectin concentrations and decrease concentrations of 
leptin, promoting a phenotype associated with a healthy BMI [30].  Additionally, dietary 
DHA has also been described as a possible appetite suppressor through actions that 
promote the release of the anorexogenic protein pro-opiomelanocortin (POMC) from 
neurons of the hypothalamus [31]. 
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There is also evidence for DHA acting as a ligand for both intracellular and cell 
surface receptors [27].  DHA has been demonstrated to bind the transcription factor PPARγ, 
expressed in adipose tissue as demonstrated in Figure 5 [27].  The PPARγ receptor, once 
having bound its ligand, may interact with the transcription factor NF-κB or it may 
dimerize with an activated retinoic-X-receptor, altering gene transcription within the cell 
[32].  The latter action appears to be involved in promoting production of proteins related 
to a healthier phenotype, including adiponectin and adipose differentiation related protein 
(ADRP) which appear to promote greater fatty acid oxidation and increased energy 
expenditure by way of protein uncoupling [32].   
                                       
Figure 5: Activation of PPARγ by DHA 
Adipo: adiponectin, ADRP: adipose differentiation related protein, ap2: adipocyte protein 2, 
C/EBP: CCAAT/enhancer-binding proteins, COX: cyclooxygenase, IL-1: interleukin 1, LPL: 
lipoprotein lipase, NF-KB: nuclear factor kappa B, PPAR: peroxisome proliferator-activated 
receptor, PUFA: polyunsaturated fatty acid, RE: response element, RXR: retinoic acid 





E.  DHA AND AFFECTS ON BODY COMPOSITION 
 Relatively few well-controlled studies have assessed the impact of omega-3 fatty 
acids on body composition in humans and markers of a healthy phenotype, however animal 
research provides evidence suggesting omega-3 fatty acids can play a role in reducing body 
fat and improve bone mineralization.  Additionally, even fewer studies have been 
conducted in pregnant cohorts.  The results of those studies that have been conducted in 
humans appear to be inconsistent. 
In a double-blinded, randomized controlled trial of overweight and obese men and 
women, Gammelmark and others showed omega-3 fatty acids to increase serum 
adiponectin levels [33].  Overweight and obese participants (n= 49, mean BMI = 30.2 
kg/m2) were randomly assigned to one of two groups, receiving supplements containing 
either 2g/d olive oil (control) or 2g/d (640 mg EPA, 480 mg DHA) of fish oil for 6 weeks.  
Serum concentrations of adiponectin increased significantly (p = 0.04) from baseline 
concentrations after 6 weeks of supplementation with fish oil when compared to the 
control, however no significant changes in other markers of inflammation (i.e. TNF- , IL-6, 
CRP) were observed [33].  In the marine omega-3 supplementation group, an inverse 
correlation was observed between serum adiponectin and anthropometric measures of 
BMI and waist circumference.  Additionally, serum adiponectin concentrations were 
independently associated with fish oil supplementation; BMI, waist circumference, low-
density lipoprotein (LDL-C), total cholesterol, and circulating triacylglyerols did not 
significantly differ between baseline and post-intervention [33].   
 Using a randomized, double-blinded, 2-way parallel study design, Harden and 
colleagues assigned female subjects (n=40, BMI = 30.4 ±3.7) to one of two groups, 
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supplementing either a DHA emulsion (2.8g/d) or an oleic acid (OA) emulsion (unspecified 
amount per day) taken as 6 mL doses twice daily [34].  Energy intake, calculated from self-
reported 3-day food diaries provided at baseline and after 12 weeks of intervention, 
proved to be significantly reduced (p = 0.02) in the DHA group compared to those taking 
OA supplements after intervention [34].  Additionally, in both groups reductions in BM) Δ 
from baseline = -0.8 kg/m2 OA group, -1.3 kg/m2 D(A group  and body fat percentage Δ 
from baseline = -5.6% OA group, -5.9% DHA group) were observed, however statistical 
significance between groups was not found [34].  Overall body weight was also reduced after D(A provision Δ from baseline = - .  kgs  and OA supplementation Δ from baseline 
= -1.4 kgs), however statistical significance was not achieved (p= 0.89) [34].  
 Kabir organized a double-blind, parallel designed study in which female participants 
(n=27) previously diagnosed with type 2 diabetes mellitus were randomly assigned to 
supplement either 3g/d fish oil (1.08g EPA, 0.78g DHA) or a paraffin oil placebo for 2 
months [35].  In addition to supplementation, participants were advised to consume their 
recommended diet (total kcals distributed as 55% CHOs, 15% protein, and 30% fat) more 
strictly, to maintain a consistent dietary intake for the duration of the study, and were 
asked to complete 7 day food diaries both pre- and post-intervention to assess compliance 
to the recommendations. To assess changes to body composition, dual-energy X-ray 
absorptiometry (DEXA) scans and computerized tomography (CT) scans were performed.  
Additionally, fasting blood samples were taken to measure plasma adipokines (leptin, 
adiponectin, IL-6, and TNF-  and plasminogen activator-inhibitor 1 (PAI-1).  Fat biopsies 
were also taken to determine changes in gene expression and adipocyte size [35].  Body 
weight did not change, however supplementation with fish oil proved to significantly 
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decrease total percent body fat (p = 0.02) and adipocyte diameter (p = 0.002) when 
comparing groups, controlling for baseline values [35].  Adiponectin proved to negatively 
correlate with atherogenic index values (r = -0.44, p = 0.015), however no significant 
relationships were detected regarding the remainder of plasma biomarkers [35]. 
F. SUMMARY AND PURPOSE 
 Pregnancy and lactation have been postulated as possible transitional periods 
regarding female health, specifically regarding risk for weight retention and poor bone 
mineralization.  These time periods may be appropriate times for intervention.  
Breastfeeding has been indicated in promoting postpartum weight loss.  Routine physical 
activity and DHA intake have been implicated in promoting bone health.  In reviewing 
recent literature, few inquiries appear to have been made attempting to establish the 
relationships between breastfeeding, physical activity, measures of body composition, and 
DHA status and daily intakes.   
Therefore, the purpose of this study was to examine aforementioned relationships 
in a group of women 2 to 3 years postpartum. Hypotheses were:  (1) physical activity status 
would be positively associated with measures of bone mineralization, while inversely 
associated with measures of adiposity;  (2) duration of breastfeeding would be positively 
correlated with increased bone mineralization and inversely associated with adiposity, 
independent of physical activity status; and (3) circulating DHA concentrations would be 
inversely associated with adiposity and positively associated with bone mineralization in 
the inter-partum period, and would further strengthen the relationship between physical 





 The time periods of pregnancy and lactation are regarded as possible transitional 
periods regarding female health.  An estimated 15 to 20% of recently pregnant women will 
retain ≥ 5kg (10.4 lbs) of their gestational weight gain at 12 months postpartum [7].   
Additionally, these time periods are times of well-documented, high rates of bone turnover.  
Thus, these periods in life may be appropriate times for nutritional intervention to 
attenuate the possibility of transition toward poor health [11].  Postpartum breastfeeding 
is associated with a reduction in gestational weight retention.  Additionally, physical 
activity is known to positively affect bone mineralization.  However few inquiries into the 
relationships between breastfeeding, physical activity, and body composition postpartum 
have been made.  Additionally, no studies to our knowledge have examined how dietary 
intake of docosahexaenoic acid (DHA), may contribute to explaining any associations that 
exist between body composition, breastfeeding duration, and bone density in the inter-
partum period.  In animal studies, DHA has shown to possibly increase calcium absorption 
within the small intestine and to limit osteoclastic maturation via arachidonic acid (AA) 
displacement within osteoblastic cell membranes, reducing the availability of AA for 
production of osteoclast stimulating metabolites such as prostaglandin-2 (PGE2) [29].   The 
implication is that DHA may positively affect bone mineralization. 
Therefore, the purpose of this study was to examine possible associations between 
postpartum body composition, levels of physical activity, breastfeeding duration, dietary 
DHA intake, and circulating levels of DHA at 2 to 3 years postpartum. Additionally 
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examined were if possible relationships were further associated with DHA status.  
Hypotheses were:  (1) physical activity status would be positively associated with 
measures of bone mineralization, while inversely associated with measures of adiposity;  
(2) duration of breastfeeding would be positively correlated with increased bone 
mineralization and inversely associated with adiposity, independent of physical activity 
status; and (3) circulating DHA concentrations would be inversely associated with 
adiposity and positively associated with bone mineralization in the inter-partum period, 




METHODS AND PROCEDURES 
 
A.  Recruitment of Participants 
The Colorado State University Internal Review Board Human Subjects Committee 
approved the study protocol before study initiation.  The current project was a follow-up 
study to the Omega Smart Baby (OSB) study, a double-blind randomized placebo controlled 
trial in which women were provided either placebo or fish oil supplementation beginning 
in the final trimester of pregnancy and continuing to 3 months postpartum.  Outcomes such 
as gestation length, infant neurological development, and concentrations of DHA within 
breastmilk were measured.  All 116 women who participated in the previous OSB project 
were contacted regarding enrollment in the follow-up study.  Contact with these mothers 
was maintained from conclusion of the OSB project and all contact information has been 
kept on file with Colorado State University (CSU).  A research associate working with CSU 
conducted first contact with eligible participants.  During initial contact, individuals were 
asked of their interest in participation in a follow-up study and their current pregnancy 
status.  Women expressing interest in participating in the follow-up study, who self-
reported not being pregnant during the previous 24 months, were contacted by a graduate 
research assistant to further discuss details of the present study.  Twenty-one women 
contacted provided verbal intent to participate in the present study.   Women enrolled 
were those who met the aforementioned criteria and were exempt from any exclusionary 
criteria.  Exclusionary criteria, in addition to not being pregnant during the previous 24 
months, were diagnosis of type 2 diabetes mellitus, hyperparathyroidism, celiac disease, 
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osteopenia, osteoporosis, rheumatoid arthritis, or use of medications that may alter bone 
density.  Upon agreement to participate in the study, participants scheduled a time to meet 
with the graduate research assistant at the Human Performance and Clinical Research 
Laboratory (HPCRL) on the CSU campus. 
An additional 6 parous women, matched for age, were recruited from the 
community for enrollment to act as a comparison group.  Those eligible for participation 
were women aged 18-40, without pregnancy during the previous 36 months and did not 
self-report medical diagnoses that would exclude them from the study.  Possible 
participants were recruited from places frequented by mothers of young children, i.e. child care centers, local health clubs that offer child care services, and CSU’s Early Childhood 
Center (ECC). Flyers for the project were distributed at many childcare centers and health 
clubs across the Fort Collins, Colorado community.  The flyer (appendix A) provided a brief 
synopsis of the project, what would be needed of the participants, and contact information 
for the graduate research assistant.   Upon contact with interested individuals, 
confirmation of eligibility and details of the study were discussed.  Six individuals met all 
inclusionary criteria, provided consent to participate, and scheduled to meet for an 
assessment at the HPCRL.     
B.  Procedures 
 Once enrolled, participants met with trained university staff at the HPCRL on the 
main CSU campus at scheduled times for assessments ranging between 30 and 40 minutes.  
Participants were then asked to provide written consent (appendices B and C) for 
participation in the research project.  Two consent forms existed, and provision depended 
on whether or not the participant had previously participated in the OSB project.   After 
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provision of consent, individuals completed a series of questionnaires.  These included a 
demographics questionnaire that also asked about history of breastfeeding (appendix D), a 
form asking about any pre-existing conditions which may affect bone health (appendix E), a 
previously validated food frequency questionnaire (FFQ) designed to assess intake of foods 
containing DHA (appendix F), and a physical activity questionnaire (PAQ) (appendix G) 
designed by the European Prospective Investigation into Cancer (EPIC) Study – Norfolk 
research team, also previously validated [36].   
After completion of all assessment forms, a trained graduate research assistant 
obtained a 7 mL blood sample for laboratory analysis from each participant.  Blood 
collection was conducted using BD Vacutainer blood collection tubes with disodium 
ethylenediamin tetraacetic acid (EDTA) for preservation.  Samples were stored on ice for 
approximately 30 minutes before separation for final storage.  Whole body DEXA body 
composition scans using Hologic Discovery W (Hologic, Inc.) device with software version 
13.4:7 were conducted.   
Before conducting DEXA analyses, anthropometric measures of height and weight 
were taken and data were input into the DEXA software.  Upon completion of the 
assessment, participants were given a copy of their DEXA results along with an information 
sheet (appendix H) intended to assist individuals interpret the results of the analysis. This 
was viewed by the research team as an incentive to the participants for participation in the 
study. Completed questionnaires and DEXA results were kept on file in the Department of 




C.  Laboratory Analyses 
 Plasma and red blood cell (RBC) phospholipid fatty acid (FA) composition 
assessment was obtained for all subjects at assessment.  Whole blood samples were 
separated via centrifugation at 1000g x 10 minutes directly after participant assessment 
and RBCs and plasma were aliquoted and stored at -80°C for later analysis. Plasma 
phospholipids were extracted in methanol and directly methylated with sodium methoxide 
(25% w/v) using the method of Glaser, Demmelmair and Koletzko [37].  RBC samples were 
treated with a 2:1 cholorform to methanol mixture, centrifuged, and the liquid phase was 
removed and evaporated under an oxygen-free nitrogen stream to concentrate the total 
lipid fraction.  The phospholipid portions were methylated through addition of boron 
trifluoride in methanol (~14% BF3) and heated to 100°C to form fatty acid methyl esters 
(FAMEs).  FAMEs were extracted in hexanes and separated using microcapillary gas liquid 
chromatography with flame ionization detection. Individual FAMEs were identified by 
comparison of retention times with known FAME standards.  FA composition was 
expressed as percentages of total fatty acids. 
D.  Statistical Analyses 
 Statistical analyses were conducted using Statistical Package for the Social Sciences 
(SPSS) Version 22.  Bivariate and partial correlations were conducted among measures of 
body composition, circulating DHA concentrations, self-reported dietary intake of DHA, 
breastfeeding duration, weight gain during most recent pregnancy, and total metabolic 
equivalent of task (MET) hours per week as calculated from a self-reported assessment of 
physical activity.  Linear regression analyses were conducted to determine the best 
predictive models for measures of body composition which proved to be interest through 
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prior analyses. Due to many comparisons with a small number of participants, associations 






 There were 27 participants who completed measures for this study.  All 27 women 
provided blood samples, completed DEXA body composition analyses, and completed the 
food frequency, breastfeeding, and pre-existing conditions questionnaires.  Of the 
participants, 24 provided a completed physical activity questionnaire.  The majority 
identified as white (n=25) while one individual identified as African-American and one 
identified as Hispanic.  Thirteen participants indicated taking a multivitamin, including 
calcium and vitamin D, while 2 indicated taking an oral contraceptive; neither influenced 
statistical results.  One individual indicated diagnosis of celiac disease and 4 indicated a 
diagnosis of asthma.  Descriptive statistics are shown in Table 1.  Participants were 
generally of a healthy BMI, were 3 years postpartum, and breastfed for just over 1 year. 
Table 1:  Description of study sample. 
 
 N Minimum Maximum Mean Std. 
Deviation 
Age (years) 27 25.0 42.0 35.2 3.7 
Height in meters (m) 27 1.56 1.73 1.66 0.05 
Weight in kilograms (kg) 27 54.1 81.8 67.8 8.6 
Body Mass Index (kg/m2) 27 18.7 32.0 24.6 3.5 
Time Postpartum (months) 27 22.0 116.0 37.3 17.3 
Pregnancy Weight Gain (kg) 21 6.8 20.5 14.2 3.8 
Time breastfeeding (months) 21 0.5 40.0 16.4 9.6 
Time since cessation of 
breastfeeding (months) 
21 0.0 36.0 15.6 10.1 
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Correlations among bone mineralization and self-reported data regarding recent 
pregnancy and breastfeeding were conducted.  Measures of bone mineralization were not 
significantly related to time removed from pregnancy, gestational weight gain, recent 
breastfeeding duration, or time since cessation of breastfeeding.  Additionally, 
relationships between measures of adiposity, BMI, and weight and the provided pregnancy 
and breastfeeding data were also conducted.  Again, no measures of percent body fat, BMI, 
or weight significantly correlated with time since pregnancy, gestational weight gain, 
recent breastfeeding duration, or time since cessation of breastfeeding.   
All individuals completed an FFQ asking about intake of foods and supplements as 
sources of DHA.  Participants also completed a previously validated physical activity 
questionnaire, from which total metabolic equivalent of task (MET) hours per week were 
evaluated.  Average daily intake of DHA was 193.4 ± 157.4 mg/d.  Reported DHA intake 
significantly correlated with RBC DHA concentrations (r = 0.526, p = 0.005), though not 
plasma DHA concentrations.  There proved no relationship between MET hours per week 
and DHA status or intake. 
Dietary DHA intake, total MET hours per week, as well as plasma and RBC DHA 
status were assessed for relationships with measures of body composition.  Pearson 
correlation coefficients are shown in table 2.  Neither dietary intake of DHA nor plasma 
DHA status significantly associated with measures of body composition.  Both lumbar and 
pelvic BMC (bone mineral content) significantly inversely correlated with RBC DHA status 
(p = 0.023 and p = 0.017, respectively).  Total MET hours per week correlated significantly 
with lumbar BMC (p = 0.017), whole body bone mineral density (BMD) (p = 0.018), and T-
score (p = 0.017) as postulated, though no measures of percent body fat, weight, or BMI.   
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Table 2:  Pearson correlation coefficients for physical activity, DHA status, and body 
composition amongst women 2-3 years postpartum (n = 27). 
 


























* - achieved significance at p < 0.025 
** - achieved significance at p < 0.01 
BMC: bone mineral content, BMD: bone mineral density, MET: metabolic equivalents 
of task, RBC: red blood cell, DHA: docosahexaenoic acid 
 
Partial correlations controlling for possible confounding factors were run to assess 
the strength of observed correlations.  Controlling for age, BMI, and RBC DHA status, MET 
hours per week was no longer correlated with lumbar BMC, whole body BMD, and T score.  
Controlling for age, BMI, and MET hours per week, RBC DHA was inversely associated with 
lumbar (p = 0.007, r = -0.570) and pelvic (p = 0.003, r = -0.608) BMC. 
Linear regressions were run to explore the best models for explaining variance 
within variables of interest.   For lumbar BMC, the best predictive model incorporated MET 
hours per week and RBC DHA status, explaining 40.3% of the variance within the variable 
(p = 0.004).  Pelvic BMC was best explained again by MET hours per week and RBC DHA, 
explaining 42.3% of the variance (p = 0.003).  -weights and levels of significance for the 
aforementioned variables are described in tables 3 and 4.  Whole body BMD and T score 
were only significantly explained by MET hours per week at 22.9% and 23.1% of variance, 
respectively (p = 0.018 and p = 0.017). 
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Table :  β-weights and individual levels of significance for included variables in 
linear regression model for dependent variable lumbar bone mineral content (BMC). 
 
 Standardized β Significance 
(Constant) -- 0.000 
RBC DHA -0.413 0.024 
MET Hours Per Week 0.447 0.015 
 
 
Table :  β-weights and individual levels of significance for included variables in 
linear regression model for dependent variable pelvic bone mineral content (BMC). 
 
 Standardized β Significance 
(Constant) -- 0.000 
RBC DHA -0.503 0.007 









A.  DISCUSSION OF FINDINGS 
 
This cross-sectional pilot study of women recently pregnant was undertaken to 
examine the possible associations among postpartum body composition, breastfeeding, 
physical activity, and DHA status.  Positive relationships were found between habitual 
physical activity and lumbar bone mineral content (BMC), whole body bone mineral 
density (BMD), and T score, though there were no relationships with BMI, weight, or 
measures of adiposity.  It is well understood that bone mineralization is typically higher in 
exercising compared to non-exercising individuals [38].  Also, prospective studies of 
humans as well as animal studies indicate a role for physical activity in maintaining bone 
health [38].  Within the postpartum period, exercise appears to attenuate the loss of bone 
mineralization.  Lovelady et al., assigning women to either an exercise or control group at 
4-16 weeks postpartum, observed a protective effect on lumbar BMD related to exercise 
[39].  In fact, much of the body of similar literature has been conducted close to the time of 
delivery.  Participants in this study were on average 37.3 months postpartum, and findings 
add to previous research that the benefits of exercise continue to be observed as time 
moves forward.  When controlling for age, BMI, and DHA status, aforementioned 
relationships failed to remain significant.  This could imply that DHA, along with age and 
BMI, accounts for some of the positive impact on bone, however bivariate correlations 
between DHA and measures of bone mineralization as well as results from the linear 
regression models indicate an inverse relationship between DHA and bone health.  These 
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same regression models continued to indicate a positive relationship between habitual 
physical activity and bone mineralization. 
 No significant associations were found between breastfeeding duration, months 
since cessation of breastfeeding, pregnancy weight gain, or months postpartum and body 
composition.  This may be a reflection of the study timing, seeing individuals between 2 
and 3 years postpartum and on average 16 months after having last breastfed.  We know 
from prospective studies that within 6-12 months post-weaning many mothers return to 
baseline levels of bone mineralization [12].   Prolactin levels, which are high during 
lactation, support calcium release from maternal bone stores [39].  However, as time since 
delivery advances, the eventual return of menses and simultaneous increase in estrogen 
levels decrease bone resorption [39].  Still, previous studies have shown relationships 
between bone metabolism and breastfeeding.  Yeo et al. observed in a study of Korean 
women that longer duration of breastfeeding resulted in lower total femoral, femoral neck, 
and lumbar spine BMD [40].  Hopkinson et al., in a study of lactating and non-lactating 
women observed that at 24 months postpartum duration of breastfeeding (specifically 
breastfeeding for greater than 9 months) was inversely related to net regain of whole body 
BMC and, regarding thoracic spine BMC specifically, significant differences between 
lactating and non-lactating women existed out to 12 months postpartum [41].  When 
discussing specifically gestational weight gain and its relationship with bone mineralization, 
few studies have made inquiry.  Widen et al. showed that patterns in gestational weight 
gain correlated with differences in percent fat mass and total body water, but did not 
inquire into bone mineralization [42]. 
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 Finally, there were inversely significant associations between circulating levels of 
DHA and both lumbar and pelvic BMC.  Mechanistically, basis for a role for DHA is provided 
by many animal and cell-culture models, however these and human models have yet to 
consistently show a role for DHA.   Provided the mechanisms behind bone resorption, DHA and it’s action as an inhibitor of AA bioavailability could indicate a plausible role in limiting 
bone resorption, as indicated here when controlling for DHA, assessing the correlations 
observed between physical activity and bone mineralization.  However, there is also 
indication that in addition to DHA levels, another important factor is the availability of 
antioxidant nutrients.  Izquierdo and colleagues proved that high levels of DHA lead to 
peroxidation risks, and the deleterious results of high DHA levels, including damage to 
cartilaginous structures and bone formation, could be the result of free radicals [43].  Administration of -tocopherol reduced these risks [43]. 
B.  STRENGTHS AND LIMITATIONS 
 The results of this study are affected by both strengths and limitations.  In our study, 
we regard the DHA FFQ and the PAQ given to our participants at assessment as strengths.  
Both questionnaires have been previously validated and again in this study, the responses 
provided to us on the DHA FFQ are strongly correlated with RBC DHA providing further 
confidence in the measure.  Aside from being previously validated, the PAQ provided was a 
12-page assessment, asking for a thorough account of one’s habitual daily physical activity 
and therefore our calculations of total MET hours per week for participants is presumed to 
be well representative. 
 Another strength of our study is the use of DEXA analysis for analyses of body 
composition.  Kuriyan et al. in a study assessing the use of DEXA, air displacement 
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plethysmography (ADP), bio-electrical impedance, and a 4-skinfold technique to measure 
percent body fat, using a 4-compartment (4C) model as reference, found DEXA to be the 
only analysis to not underestimate percent body fat [44].  Compared to other measures of 
body composition, DEXA has a unique ease of use and allows simultaneous insight into 
both whole body and regional measurements.  DEXA has additionally been shown to be 
superior compared to other body fat measures [45]. 
 One limitation to the study is the number of participants.  In our original grant 
proposal, we wrote that our power analysis indicated the need for 36 participants 
recruited from our previous cohort.  Recruiting 36 participants from our cohort of 
previously studied women proved difficult, as many had moved from the surrounding area 
and were unavailable to meet with a member of the research team while others were 
simply not interested.  It is possible that the low number of participants in this study has 
impacted the significant observations seen. 
Another limitation of our study is the cross-sectional nature of the project.  In our 
project, we have something of a snapshot into the lives of our participants.  In their study to 
assess relationships between bone mineralization and lactation, Hopkinson et al. followed 
participants beginning shortly after delivery to 24 months postpartum collecting data at 3-
month intervals.  Were our study to have taken on a prospective design, we may have 
gained greater insight into the associations between our variables in question while also 
possibly addressing our low number of participants through collection of more data at 
multiple time points. 
 A final limitation to our project is that all but two participants identified as white, as 
one identified as African-American and one identified as Hispanic.  Per 2010 U.S. census 
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data, the Fort Collins, Colorado community from which participants were largely recruited, 
is 89.0% white and therefore participants for this study were recruited from a largely 
homogenous population.  Extrapolation of the results obtained in this study to the national 
population would thus be difficult given the ethnic disparity that exists between the 
demographics of the local community and the nation at large in addition to the 
aforementioned limitations.  
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CHAPTER VI 
CONCLUSIONS AND RECOMMENDATIONS 
 
This study of women roughly 3 years postpartum has provided additional insight 
into the relationships between body composition, physical activity and DHA status.  By 
showing associations between variables such as physical activity postpartum and bone 
mineralization, we have provided additional evidence to support the present body of 
literature.  However, any future studies should take account of study limitations and make 
changes accordingly.  Future inquiries may wish to employ a prospective design if working 
with human subjects, as was our case.  Such a design would alleviate the fact that we have 
large gaps of time for which we have no data, but instead have data from a single time point 
from which we have attempted to arrive at significant associations. 
 Finally, in our research we found recruitment of individuals, specifically new 
individuals from the community, to be difficult.  Though we used an incentive-based 
technique for recruitment and maintained relationships with previous study participants, 
giving us access to the appropriate population of individuals, our numbers remained low.  
We would recommend to other researchers the use of special events, such as asking 
recruiters to present the project idea in a more formal manner, presenting the pertinent 
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Consent to Serve as a Subject in Human Research 
(For Participants in the Omega Smart Baby Project) 
 
Title of Project:  Omega Smart Baby Project: Follow Up Study of Moms Treated with 
DHA During Pregnancy 
 




Co-Investigators:  Christopher Bell, PhD 
    Kimberly Cox-York, PhD 
     
     
WHO IS DOING THE STUDY? Colorado State University is conducting this research..    The 
study is being funded by the USDA Agricultural Experiment Station. 
 
WHAT IS THE PURPOSE OF THIS STUDY?   
The primary purpose of the study is to see if DHA taken during pregnancy and lactation 
improves your body composition (body fat and bone density) 18 months after you gave 
birth.   There is a growing body of research that shows that DHA may be involved in 
burning body fat and also in promoting bone density. Since women lose bone and increase 
body fat during pregnancy, we are testing to see if taking DHA during pregnancy and 
breastfeeding may help to restore pre-pregnancy weight and body composition.  
 
WHY AM I BEING ASKED TO PARTICIPATE IN THIS RESEARCH?  You are being asked to 
participate in this follow-up study because you were part of the Omega Smart Baby Project 
and may or may not have received a supplement of the essential nutrient (an omega-3 fatty 
acid called DHA, or docosahexaenoic acid) during pregnancy and for the first 3 months of 
breastfeeding.  
 
WHAT WILL I BE ASKED TO DO?  If you agree to be in the study, you will come into the 
Human Performance laboratory at Colorado State University to have a DEXA bone density 
and body composition test.  At that same time, we will ask you to provide a small follow-up 
blood sample (10 ml or about 2 teaspoons) for analysis of your DHA stores and blood 
markers of inflammation and body fat metabolism and to fill out a one-page food intake 
and supplement form.  We will measure and record your height and body weight. 
 
What is a DEXA?DEXA is an FDA approved device for the measurement of bone density. 
Dual X-ray absorptiometry (DEXA) is the preferred technique for measuring  
bone density.  The DEXA scanner produces 2 X-ray beams, each with different energy levels. 
One beam is high energy while the other is low energy. The amount of X-rays that pass 
through the bone is measured for each beam. This will vary depending on the thickness of 
the bone. The DEXA test is relatively easy to perform, you simply lay flat on a platform for 
about 20 minutes as the scanner moves over you. The amount of x-ray exposure is very low. 
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Dose from the DEXA measurement is well below natural background radiation levels.  For 
example, total average x-ray exposure with the DEXA is around 0.2 microSv (units used to 
describe radiation) compared to dental bitewing xray 60 microSv  and 5000 times lower 
than the recommended daily limit of 1000 micro Sv/day. 
 
WHERE WILL THE STUDY TAKE PLACE?All testing will take place in the Human 
Performance Laboratory in Moby Gym at Colorado State University.  
 
HOW LONG WILL THE STUDY LAST?  The study will take about 30 minutes of your time.   
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?   It is not possible to identify 
all potential risks in a research procedure, but the researchers have taken reasonable precautions to 
minimize any known and potential, but unknown, risks. There are no anticipated physical risks for 
participating in the DEXA test other than a very small amount of radiation (equal to about 15 minutes 
outside on a sunny day). This is a commonly used clinical test to measure bone density and risk for 
osteoporosis in women.    The risks of blood drawing are: a possible hematoma (bruise) at the site where 
blood was drawn and the remote risk of infection. There are no other known or anticipated risks 
associated with the study other than those addressed above.The results of the study will be published 
BUT information will be combined with that of other people taking part in the study and you will 
NOT be identified by name in any written or oral communication. 
 
WHAT ARE THE BENEFITS OF PARTICIPATION IN THE STUDY?You will receive the 
results of your free DEXA scan (both your body fat composition and your bone density 
compared to expected values for your age).  It is anticipated that this study will contribute 
understanding of the role of omega-3 DHA status in regulating body weight and bone 
density.  
 
WILL I RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY? You will not 
receive any compensation other than the results of your DEXA. 
 
WHAT WILL IT COST ME TO PARTICIPATE? There will be no costs to you.  You will 
receive a prepaid permit for parking on campus. 
 
DO I HAVE TO TAKE PART IN THE STUDY?/ CAN MY TAKING PART IN THE 
STUDY END EARLY?  Your participation in this research is voluntary.  If you decide to 
participate in the study, you may withdraw your consent and stop participating at any time 
without penalty or loss of benefits to which you are otherwise entitled. 
 
WHO WILL SEE THE INFORMATION THAT I GIVE?    
The results of the study will be published BUT information will be combined with that of other 
people taking part in the study and you will NOT be identified by name in any written or oral 
communication.  The only exceptions to this are if we are asked to share the research files for 
audit purposes with the CSU Institutional Review Board ethics committee, if necessary. In 
addition, for funded studies, the CSU financial management team may also request an audit of 
research expenditures. For financial audits, only the fact that you participated would be shared, 
not any research data.  
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We will use your original study number to record your DEXA and blood results.   You will be 
given an envelope to fill out your name and address so that we can send your DEXA report to 
you.   We will ask you to access your medical record from your pregnancy to determine the 
amount of weight gained during your pregnancy and bring that information with you to the 




WHAT HAPPENS IF I AM INJURED BECAUSE OF THE RESEARCH?  The Colorado 
Governmental Immunity Act determines and may limit Colorado State University's legal 
responsibility if an injury happens because of this study. Claims against the University must 
be filed within 180 days of the injury. 
 
WHAT IF I HAVE QUESTIONS?       
Before you decide to accept this invitation to take part in the study, please ask any 
questions that might come to mind.  Later, if you have questions about the study, you can 
contact the investigator, Dr. Mary Harris at 970-491-7462.If you have any questions about 
your rights as a volunteer in this research, contact the CSU IRB at:  
RICRO_IRB@mail.colostate.edu; 970-491-1553.  We will give you a copy of this consent 
form to take with you. 
 
Your signature acknowledges that you have read the information stated and willingly sign 
this consent form.  Your signature also acknowledges that you have received, on the date 




Participant name (printed)  
    
_________________________________  _________________ 
Participant Signature     Date 
 
__________________________________  ___________________ 
































Consent to Serve as a Subject in Human Research 
 
Title of Project:  Omega Smart Baby Project: Follow Up Study of Moms Treated with 
DHA During Pregnancy 
 




Co-Investigators:  Christopher Bell, PhD 
    Kimberly Cox-York, PhD 
     
     
WHO IS DOING THE STUDY? Colorado State University is conducting this research.    The 
study is being funded by the USDA Agricultural Experiment Station. 
 
WHAT IS THE PURPOSE OF THIS STUDY?   
The primary purpose of the study is to see if omega-3 DHA status has an effect on body 
composition and bone density.  There is a growing body of research that shows that DHA 
may be involved in burning body fat and also in promoting bone density.  Since body fat 
increases and bone density decreases during pregnancy, this study will compare the effect 
of omega-3 DHA in women who have recently been pregnant to those who have not had a 
recent pregnancy. 
 
WHY AM I BEING ASKED TO PARTICIPATE IN THIS RESEARCH?  You are being asked to 
participate in this follow-up study because you have had children but have not been 
pregnant for at least three years.  Your data will be used to compare to women who were 
part of our recent Omega Smart Baby Project received supplements of the essential 
nutrient (an omega-3 fatty acid called DHA, or docosahexaenoic acid) during pregnancy 
and for the first 3 months of breastfeeding.  
 
WHAT WILL I BE ASKED TO DO?  If you agree to be in the study, you will come into the 
Human Performance Laboratory at Colorado State University to have a DEXA bone density 
and body composition test.  For the DEXA scan all you will need to do is to lay flat on a table 
fully clothed in comfortable clothing for about 20 minutes while the scanner moves over 
your body.  At that same time, we will ask you to provide a small blood sample (10 ml or 
about 2 teaspoons) for analysis of your DHA stores and blood markers of inflammation and 
body fat metabolism and to fill out a one-page food intake and supplement form.  We will 





What is a DEXA?DEXA is an FDA approved device for the measurement of bone density. 
Dual X-ray absorptiometry (DEXA) is the preferred technique for measuring bone density.  
The DEXA scanner produces 2 X-ray beams, each with different energy levels. One beam is 
high energy while the other is low energy. The amount of X-rays that pass through the bone 
is measured for each beam. This will vary depending on the thickness of the bone. The 
amount of x-ray exposure is very low. Dose from the DEXA measurement is well below 
natural background radiation levels.  For example, total average x-ray exposure with the 
DEXA is around 0.2 microSv  (units used to describe radiation) compared to dental 
bitewing xray 60 microSv  and 5000 times lower than the recommended daily limit of 1000 
micro Sv/day. 
        
WHERE WILL THE STUDY TAKE PLACE?All testing will take place in the Human 
Performance Laboratory in Moby Gym at Colorado State University.  
 
HOW LONG WILL THE STUDY LAST?  The study will take about 30 minutes of your time.   
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?   It is not possible to identify 
all potential risks in a research procedure, but the researchers have taken  
reasonable precautions to minimize any known and potential, but unknown, risks. There are no 
anticipated physical risks for participating in the DEXA test other than a very small amount of 
radiation (equal to about 15 minutes outside on a sunny day). This is a commonly used clinical test 
to measure bone density and risk for osteoporosis in women.    The risks of blood drawing are: a 
possible hematoma (bruise) at the site where blood was drawn and the remote risk of infection. 
The results of the study will be published BUT information will be combined with that of 
other people taking part in the study and you will NOT be identified by name in any written 
or oral communication.There are no other known or anticipated risks associated with the study 
other than those addressed above. 
 
WHAT ARE THE BENEFITS OF PARTICIPATION IN THIS STUDY? You will receive the 
results of your free DEXA scan (both your body fat composition and your bone density 
compared to expected values for your age).  It is anticipated that this study will contribute 
understanding of the role of omega-3 DHA status in regulating body weight and bone 
density.  
 
WILL I RECEIVE ANY COMPENSATION FOR TAKING PART IN THIS STUDY? You will not 
be compensated other than to receive the results of your DEXA. 
 
WHAT WILL IT COST ME TO PARTICIPATE? There will be no costs to you.  You will 
receive a prepaid permit for parking on campus. 
 
DO I HAVE TO TAKE PART IN THE STUDY?/ CAN MY TAKING PART IN THE 
STUDY END EARLY?  Your participation in this research is voluntary.  If you decide to 
participate in the study, you may withdraw your consent and stop participating at any time 




WHO WILL SEE THE INFORMATION THAT I GIVE?    
The results of the study will be published but the information will be combined with that of other 
people taking part in the study and you will NOT be identified by name in any written or oral 
communication. The only exceptions to this are if we are asked to share the research files for 
audit purposes with the CSU Institutional Review Board ethics committee, if necessary. In 
addition, for funded studies, the CSU financial management team may also request an audit of 
research expenditures. For financial audits, only the fact that you participated would be shared, 
not any research data.  
 
We will use a coded study number to record your DEXA and blood results. You will be given 
an envelope to fill out your name and address so that we can send your DEXA report to you.    
 
WHAT HAPPENS IF I AM INJURED BECAUSE OF THE RESEARCH?  The Colorado 
Governmental Immunity Act determines and may limit Colorado State University's legal 
responsibility if an injury happens because of this study. Claims against the University must 
be filed within 180 days of the injury. 
 
WHAT IF I HAVE QUESTIONS?       
Before you decide whether to accept this invitation to take part in the study, please ask any 
questions that might come to mind.  Later, if you have questions about the study, you can 
contact the investigator, Dr. Mary Harris at 970-491-7462.If you have any questions about 
your rights as a volunteer in this research, contact the CSU IRB at:  
RICRO_IRB@mail.colostate.edu; 970-491-1553.  We will give you a copy of this consent 
form to take with you. 
 
 
Your signature acknowledges that you have read the information stated and willingly sign 
this consent form.  Your signature also acknowledges that you have received, on the date 




Participant name (printed)  
    
_________________________________  _________________ 
Participant Signature     Date 
 
__________________________________  ___________________ 
























FOLLOW-UP DEMOGRAPHIC DATA COLLECTION FORM  
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Omega Smart Baby: Follow-Up Study DATA Collection Form 
 
Subject Code Number:      Date: 
 
Date of Birth:  
Participation in Any Other Study?    Yes             No 
Height (inches): 
Weight (pounds): 
Months since birth of last child: 
 
For Omega Smart Baby Participants Only 
Pregnancy Weight Gain (pounds): 
Months of Breastfeeding: 




___ Dexa completed 
___ Blood Drawn 























BONE DENSITY STUDY QUESTIONNAIRE  
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Bone Density Study Questionnaire 
 
Date of Birth_______________              Study Number_______ 
       
Are you pregnant?     Yes  No 
Are you breastfeeding?    Yes  No 
Have you been diagnosed with: 
Rheumatoid arthritis?    Yes  No 
Celiac Disease?     Yes  No 
Hyperparathyroidism?   Yes  No 
Osteopenia?     Yes  No 
Osteoporosis?     Yes  No 
Diabetes (type 1)    Yes  No 
Asthma      Yes  No  
Multiple Sclerosis or Lupus   Yes  No 
Liver Disease     Yes  No 
Kidney Disease     Yes   No 
 
Please list all medications and supplements (vitamins, minerals, 

























Thank you for your time and assistance with this study.  Your input will help other women 
in the future.      




Food Frequency Questionnaire    Study Number _______ 
 
Please provide information regarding the consumption of the following foods over the past 12 months. 
 
1)    Salmon/Trout     
___  times per day, week or month 
  (circle one) 
 
 
2)    White tuna            
(also called albacore tuna) 
___  times per day, week or month  
  (circle one) 
 
3)    Light tuna        
___  times per day, week or month 
  (circle one) 
 
4)     Sardines/        
 Herring/Anchovies 
___  times per day, week or month 
  (circle one) 
 
 
5)     Pork/Beef/Lamb   
___  times per day, week or month 




6)     Chicken/Turkey   
___  times per day, week or month 
  (circle one) 
 
7)     Eggs           
___  times per day, week or month 
  (circle one) 
 
 
8)     Goldcircle or Store   
 brand Omega-3 eggs 
___  times per day, week or month 
  (circle one) 
9)     Milk            
 With DHA?    Yes   No 
___  times per day, week or month 
  (circle one) 
 
10)   Cheese      
___  times per day, week or month 
  (circle one) 
 
 
11)   Cod liver oil      
 or other fish oils  
___  times per day, week or month  
(circle one) 
 
12)   DHA      
(docosahexanoic acid) or Omega 3      
fatty acid or fish oil supplement 
        Brand ____________________ 
        Amount of DHA/EPA_______ 
___  times per day, week or month 












































































Interpretation of Your Bone Density Test 
 Your bone density scores in your hip and spine, which are printed on the DEXA report, are shown as T-scores  and Z-scores .  The T-score represents deviation from the average bone density of healthy adult women. The Z-score represents deviation from the average bone density compared to women your exact age. The World (ealth Organization defines Osteoporosis as a T-score of - .  or more and Osteopenia low bone density  as a T-score of  -  to - . . Since deviations in T-scores increase your risk of bone fractures, you should consult your family physician if you have negative scores. Your Z-score is used to classify the type of osteoporosis.  A Z-score of < .  is usually indicative of age related bone loss or primary osteoporosis  seen in older women. A Z-score of .  and higher indicates secondary osteoporosis, which can be caused by too much or too little parathyroid hormone, rheumatoid arthritis,diabetes, celiac disease or the use of certain medications. 
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Interpretation of Your Percent Body Fat 
Your percent body fat is dependent upon a number of 
factors including age and fitness level, but there is no one ideal  number.  The American College on Exercise 
(ACE) has published recommended ranges of body fat 
for healthy individuals.  In women these ranges are: 
Athletes   14 -20% 
Fitness   21 – 24% 
Average   25 – 31% 
Above Average >32% 
The ACE ranges do not take age into consideration.  For 
adults, a range of 21 – 33% body fat is generally considered to be healthy .  )t is thought that underfat  
may be unhealthy.  For a woman between 20 – 40 years of age, less than % represents underfat .  You can 
also use the chart provided as a guide based on age but 
remember that an active person with higher body fat 
can be healthier that an inactive lean person. 
 
 
 
